RU2003101965A - TREATMENT OF INFECTION CAUSED BY HUMAN PAPILLOMA VIRUS - Google Patents

TREATMENT OF INFECTION CAUSED BY HUMAN PAPILLOMA VIRUS

Info

Publication number
RU2003101965A
RU2003101965A RU2003101965/14A RU2003101965A RU2003101965A RU 2003101965 A RU2003101965 A RU 2003101965A RU 2003101965/14 A RU2003101965/14 A RU 2003101965/14A RU 2003101965 A RU2003101965 A RU 2003101965A RU 2003101965 A RU2003101965 A RU 2003101965A
Authority
RU
Russia
Prior art keywords
subject
protein
hpv
type
hsp
Prior art date
Application number
RU2003101965/14A
Other languages
Russian (ru)
Other versions
RU2282461C2 (en
Inventor
Джон НИФ
Стефен ГОЛДСТОУН
Марк УИННЕТТ
Марвин СИДЖЕЛ
Лесли БУ
Original Assignee
Стрессджен Байотекнолоджиз Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Стрессджен Байотекнолоджиз Корпорейшн filed Critical Стрессджен Байотекнолоджиз Корпорейшн
Publication of RU2003101965A publication Critical patent/RU2003101965A/en
Application granted granted Critical
Publication of RU2282461C2 publication Critical patent/RU2282461C2/en

Links

Claims (39)

1. Способ лечения бородавки у субъекта, включающий идентификацию субъекта, у которого есть или предполагается наличие бородавки, и включающий введение субъекту композиции, включающей слитый белок, включающий (1) белок теплового шока (hsp) или его иммуностимуляторный фрагмент и (2) белок вируса папилломы человека (HPV) или его антигенный фрагмент, при том, что композицию вводят в количестве, достаточном для лечения бородавки.1. A method of treating a wart in a subject, comprising identifying a subject who has or is suspected of having a wart, and comprising administering to the subject a composition comprising a fusion protein comprising (1) heat shock protein (hsp) or an immunostimulatory fragment thereof and (2) virus protein human papilloma (HPV) or its antigenic fragment, despite the fact that the composition is administered in an amount sufficient to treat a wart. 2. Способ по п.1, отличающийся тем, что hsp является микобактериальным hsp.2. The method according to claim 1, characterized in that hsp is mycobacterial hsp. 3. Способ по п.2, отличающийся тем, что микобактериальный hsp является hsp Mycobacterium bovis.3. The method according to claim 2, characterized in that the mycobacterial hsp is hsp Mycobacterium bovis. 4. Способ по п.3, отличающийся тем, что hsp является Hsp65 Mycobacterium bovis.4. The method according to claim 3, characterized in that the hsp is Hsp65 Mycobacterium bovis. 5. Способ по п.1, отличающийся тем, что hsp является членом семейства белков Hsp60 или Hsp70.5. The method according to claim 1, characterized in that hsp is a member of the Hsp60 or Hsp70 protein family. 6. Способ по п.1, отличающийся тем, что HPV является HPV типа 16.6. The method according to claim 1, characterized in that the HPV is type 16 HPV. 7. Способ по п.1, отличающийся тем, что белок HPV является белком Е7.7. The method according to claim 1, characterized in that the HPV protein is an E7 protein. 8. Способ по п.1, отличающийся тем, что композиция содержит приблизительно 50-5000 мкг слитого белка.8. The method according to claim 1, characterized in that the composition contains approximately 50-5000 μg of fusion protein. 9. Способ по п.8, отличающийся тем, что композиция содержит приблизительно 100-2000 мкг слитого белка.9. The method according to claim 8, characterized in that the composition contains approximately 100-2000 μg of fusion protein. 10. Способ по п.1, отличающийся тем, что композицию вводят без адъюванта.10. The method according to claim 1, characterized in that the composition is administered without adjuvant. 11. Способ по п.1, отличающийся тем, что субъектом является млекопитающее.11. The method according to claim 1, characterized in that the subject is a mammal. 12. Способ по п.11, отличающийся тем, что млекопитающим является человек.12. The method according to claim 11, characterized in that the mammal is a human. 13. Способ по п.1, отличающийся тем, что слитый белок вводят в количестве, достаточном для уменьшения размера бородавки.13. The method according to claim 1, characterized in that the fusion protein is administered in an amount sufficient to reduce the size of the wart. 14. Способ лечения у субъекта заболевания или состояния, связанного с вирусом папилломы человека (HPV), включающий введение субъекту композиции, содержащей слитый белок, содержащий (1) hsp или его иммуностимуляторный фрагмент и (2) белок HPV или его антигенный фрагмент, при том, что субъект инфицирован типом HPV, который отличается от типа HPV, вводимого субъекту, причем композицию вводят в количестве, достаточном для лечения заболевания или состояния.14. A method of treating a subject for a disease or condition associated with human papillomavirus (HPV), comprising administering to the subject a composition comprising a fusion protein comprising (1) hsp or an immunostimulatory fragment thereof and (2) an HPV protein or antigenic fragment thereof, that the subject is infected with a type of HPV that is different from the type of HPV administered to the subject, the composition being administered in an amount sufficient to treat a disease or condition. 15. Способ по п.14, отличающийся тем, что hsp является микобактериальным hsp.15. The method according to 14, characterized in that hsp is mycobacterial hsp. 16. Способ по п.15, отличающийся тем, что микобактериальный hsp является hsp Mycobacterium bovis.16. The method according to clause 15, wherein the mycobacterial hsp is hsp Mycobacterium bovis. 17. Способ по п.16, отличающийся тем, что hsp является Hsp65 Mycobacterium bovis.17. The method according to clause 16, wherein the hsp is Hsp65 Mycobacterium bovis. 18. Способ по п.14, отличающийся тем, что hsp является членом семейства белков Hsp60 или Hsp70.18. The method according to 14, characterized in that hsp is a member of the Hsp60 or Hsp70 protein family. 19. Способ по п.14, отличающийся тем, что тип HPV, вводимого субъекту, является типом 16.19. The method according to 14, characterized in that the type of HPV administered to the subject is type 16. 20. Способ по п.19, отличающийся тем, что субъект страдает заболеванием или состоянием, связанным с HPV типа 5, 6, 11, 18, 31, 33, 35, 45, 54, 60 или 70.20. The method according to claim 19, characterized in that the subject suffers from a disease or condition associated with HPV type 5, 6, 11, 18, 31, 33, 35, 45, 54, 60 or 70. 21. Способ по п.20, отличающийся тем, что субъект страдает заболеванием или состоянием, связанным с HPV типа 6, 11, 33, 45 или 70.21. The method according to claim 20, characterized in that the subject suffers from a disease or condition associated with HPV type 6, 11, 33, 45 or 70. 22. Способ по п.21, отличающийся тем, что субъект страдает заболеванием или состоянием, связанным с HPV типа 6 или 11.22. The method according to item 21, wherein the subject suffers from a disease or condition associated with type 6 or 11 HPV. 23. Способ по п.14, отличающийся тем, что белок HPV является белком Е7.23. The method according to 14, characterized in that the HPV protein is an E7 protein. 24. Способ по п.14, отличающийся тем, что композиция содержит приблизительно 50-5000 мкг слитого белка.24. The method according to 14, characterized in that the composition contains approximately 50-5000 μg of fusion protein. 25. Способ по п.24, отличающийся тем, что композиция содержит приблизительно 100-2000 мкг слитого белка.25. The method according to paragraph 24, wherein the composition contains approximately 100-2000 μg of fusion protein. 26. Способ по п.14, отличающийся тем, что композицию вводят без адъюванта.26. The method according to 14, characterized in that the composition is administered without adjuvant. 27. Способ по п.14, отличающийся тем, что субъектом является млекопитающее.27. The method according to 14, characterized in that the subject is a mammal. 28. Способ по п.27, отличающийся тем, что млекопитающим является человек.28. The method according to item 27, wherein the mammal is a human. 29. Способ по п.14, отличающийся тем, что субъект не идентифицирован как являющийся инфицированным типом HPV, который вводят перед введением композиции.29. The method according to 14, characterized in that the subject is not identified as being an infected type of HPV, which is administered before the introduction of the composition. 30. Способ лечения бородавки у субъекта, включающий идентификацию субъекта, у которого есть или предполагается наличие бородавки; введение субъекту нуклеиновой кислоты, кодирующей слитый белок, содержащий (1) hsp или его иммуностимуляторный фрагмент и (2) белок HPV или его антигенный фрагмент; и экспрессию слитого белка в субъекте в количестве, достаточном для лечения бородавки.30. A method of treating a wart in a subject, comprising identifying a subject who has or is suspected of having a wart; administering to the subject a nucleic acid encoding a fusion protein comprising (1) hsp or an immunostimulatory fragment thereof and (2) an HPV protein or antigen fragment thereof; and expression of a fusion protein in a subject in an amount sufficient to treat a wart. 31. Способ по п.30, отличающийся тем, что нуклеиновая кислота содержится в вирусном векторе.31. The method according to p. 30, characterized in that the nucleic acid is contained in a viral vector. 32. Способ лечения у субъекта заболевания или состояния, связанного с HPV-инфекцией, включающий введение субъекту нуклеиновой кислоты, кодирующей слитый белок, содержащий (1) hsp или его иммуностимуляторный фрагмент, и (2) белок HPV, при том, что субъект инфицирован типом HPV, который отличается от типа HPV, вводимого субъекту; и экспрессию слитого белка в количестве, достаточном для лечения этого заболевания или состояния.32. A method of treating a subject for a disease or condition associated with HPV infection, comprising administering to the subject a nucleic acid encoding a fusion protein comprising (1) hsp or an immunostimulatory fragment thereof, and (2) an HPV protein, wherein the subject is infected with a type HPV, which is different from the type of HPV administered to a subject; and expression of a fusion protein in an amount sufficient to treat this disease or condition. 33. Способ по п.32, отличающийся тем, что нуклеиновая кислота содержится в вирусном векторе.33. The method according to p, characterized in that the nucleic acid is contained in a viral vector. 34. Способ по п.14, отличающийся тем, что заболеванием или состоянием является аногенитальные бородавки, подошвенные бородавки, рак шейки матки, дисплазия шейки матки, рак прямой кишки, дисплазия прямой кишки или рецидивирующий респираторный папилломатоз.34. The method according to 14, characterized in that the disease or condition is anogenital warts, plantar warts, cervical cancer, cervical dysplasia, colorectal cancer, rectal dysplasia or recurrent respiratory papillomatosis. 35. Способ по п.32, отличающийся тем, что заболеванием или состоянием является аногенитальные бородавки, подошвенные бородавки, рак шейки матки, дисплазия шейки матки, рак прямой кишки, дисплазия или рецидивирующий респираторный папилломатоз.35. The method according to p, characterized in that the disease or condition is anogenital warts, plantar warts, cervical cancer, cervical dysplasia, colon cancer, dysplasia or recurrent respiratory papillomatosis. 36. Применение композиции, содержащей (1) белок теплового шока или его иммуностимуляторный фрагмент и (2) белок вируса папилломы человека или его антигенный фрагмент, для производства лекарственного средства для лечения бородавки.36. The use of a composition comprising (1) a heat shock protein or immunostimulatory fragment thereof and (2) a human papillomavirus protein or antigenic fragment thereof, for the manufacture of a medicament for treating a wart. 37. Применение композиции, содержащей (1) белок теплового шока или его иммуностимуляторный фрагмент и (2) белок вируса папилломы человека первого типа или его антигенный фрагмент, для производства лекарственного средства для лечения инфекции, вызванной вирусом папилломы человека второго типа, при том, что первый тип и второй тип являются различными.37. The use of a composition comprising (1) a heat shock protein or immunostimulatory fragment thereof and (2) a human papilloma virus protein of the first type or an antigenic fragment thereof for the manufacture of a medicament for treating an infection caused by a human papilloma virus of the second type, despite the fact that the first type and the second type are different. 38. Применение нуклеиновой кислоты, кодирующей слитый полипептид, содержащий (1) белок теплового шока или его иммуностимуляторный фрагмент, и (2) белок вируса папилломы человека или его антигенный фрагмент, для производства лекарственного средства для лечения бородавки.38. The use of a nucleic acid encoding a fusion polypeptide containing (1) a heat shock protein or immunostimulatory fragment thereof, and (2) a human papillomavirus protein or antigen fragment thereof, for the manufacture of a medicament for treating a wart. 39. Применение нуклеиновой кислоты, кодирующей слитый полипептид, содержащий (1) белок теплового шока или его иммуностимуляторный фрагмент, и (2) белок вируса папилломы человека первого типа или его антигенный фрагмент, для производства лекарственного средства для лечения инфекции, вызванной вирусом папилломы человека второго типа, при том, что первый тип и второй тип являются различными.39. The use of a nucleic acid encoding a fusion polypeptide containing (1) a heat shock protein or immunostimulatory fragment thereof, and (2) a human papilloma virus protein of the first type or an antigenic fragment thereof, for the manufacture of a medicament for the treatment of infection caused by the human papillomavirus second type, while the first type and the second type are different.
RU2003101965/14A 2000-06-26 2001-06-26 Method for treating infection caused with human papilloma virus (hpv) RU2282461C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21420200P 2000-06-26 2000-06-26
US60/214,202 2000-06-26

Publications (2)

Publication Number Publication Date
RU2003101965A true RU2003101965A (en) 2004-07-27
RU2282461C2 RU2282461C2 (en) 2006-08-27

Family

ID=22798190

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003101965/14A RU2282461C2 (en) 2000-06-26 2001-06-26 Method for treating infection caused with human papilloma virus (hpv)

Country Status (27)

Country Link
US (4) US20020110566A1 (en)
EP (1) EP1296711B1 (en)
JP (1) JP2004512264A (en)
KR (2) KR20080075560A (en)
CN (1) CN100441223C (en)
AT (1) ATE326236T1 (en)
AU (3) AU2001271449B2 (en)
BR (1) BR0111956A (en)
CA (1) CA2413543A1 (en)
CY (1) CY1105389T1 (en)
CZ (1) CZ20024154A3 (en)
DE (1) DE60119734T2 (en)
DK (1) DK1296711T3 (en)
EE (1) EE200200709A (en)
ES (1) ES2263637T3 (en)
HR (1) HRP20021015A2 (en)
HU (1) HUP0301308A3 (en)
IL (1) IL153474A0 (en)
MX (1) MXPA02012858A (en)
NO (1) NO20026044L (en)
NZ (1) NZ523408A (en)
PL (1) PL359930A1 (en)
PT (1) PT1296711E (en)
RU (1) RU2282461C2 (en)
SK (1) SK18362002A3 (en)
WO (1) WO2002000242A2 (en)
ZA (1) ZA200210211B (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papilloma virus for use in human t cell response inducing compositions
EP1196772A2 (en) 1999-07-08 2002-04-17 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
DK1296711T3 (en) * 2000-06-26 2006-08-28 Stressgen Biotechnologies Corp HPV-E7 for the treatment of human papillomavirus
AU2001278117A1 (en) 2000-08-03 2002-02-18 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
WO2005090392A1 (en) * 2004-03-16 2005-09-29 Inist Inc. Tat-based tolerogen compositions and methods of making and using same
WO2002062959A2 (en) 2001-02-05 2002-08-15 Stressgen Biotechnologies Corp. Hepatitis b virus treatment
US6649402B2 (en) * 2001-06-22 2003-11-18 Wisconsin Alumni Research Foundation Microfabricated microbial growth assay method and apparatus
WO2004037175A2 (en) * 2002-10-21 2004-05-06 Mgi Pharma Biologics, Inc. Compositions and methods for treating human papillomavirus-mediated disease
EA200701633A1 (en) * 2002-12-20 2007-12-28 Глаксосмитклайн Байолоджикалс С.А. VACCINE BASED ON VIRUS-LIKE PARTICLES OF THE HUMAN PAPILLOMA VIRUS 16 AND HUMAN PAPILE VOLUS 18 L1
WO2004098526A2 (en) * 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
CA2526720C (en) 2003-05-22 2013-10-22 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
DE10347710B4 (en) * 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Recombinant vaccines and their use
WO2005041880A2 (en) * 2003-10-29 2005-05-12 Science & Technology Corporation @ Unm RhPV AS A MODEL FOR HPV-INDUCED CANCERS
DE10357677A1 (en) * 2003-12-10 2005-07-14 Greiner Bio-One Gmbh Primers and probes for detecting genital HPV genotypes
WO2005090968A1 (en) * 2004-03-16 2005-09-29 Inist Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
AU2005322960A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
US8252893B2 (en) * 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
JP5106384B2 (en) * 2005-04-27 2012-12-26 ライデン ユニバーシティ メディカル センター Method and means for treating HPV-induced intraepithelial neoplasia
EP1919504B1 (en) * 2005-08-03 2013-10-16 iBio, Inc. Antibody to bacillus anthracis protective antigen
US7622121B2 (en) * 2005-09-21 2009-11-24 New York University Heat shock proteins from Mycobacterium leprae and uses thereof
BRPI0707779B8 (en) * 2006-02-13 2021-05-25 Fraunhofer Usa Inc isolated antigen, vaccine composition and method for producing an antigen protein
JP2009526526A (en) * 2006-02-13 2009-07-23 フラウンホーファー ユーエスエー， インコーポレイテッド Influenza antigens, vaccine compositions, and related methods
WO2008048344A2 (en) * 2006-02-13 2008-04-24 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
US20110142873A1 (en) * 2006-05-31 2011-06-16 Gerry Rowse Bioactive purified hspe7 compositions
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080311145A1 (en) * 2007-04-04 2008-12-18 Specigen, Inc. Protein cage immunotherapeutics
BRPI0810865A2 (en) * 2007-04-28 2017-05-09 Fraunhofer Usa Inc trypanosome antigens, vaccine compositions, and related methods
CA2692933C (en) 2007-07-11 2016-10-18 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
WO2009026397A2 (en) * 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
US20090117140A1 (en) * 2007-09-26 2009-05-07 Mayumi Nakagawa Human papilloma virus dominant CD4 T cell epitopes and uses thereof
WO2009094006A2 (en) * 2007-10-25 2009-07-30 Wake Forest University Health Sciences Bordetella outer-membrane protein antigens and methods of making and using the same
DK2257301T3 (en) 2008-03-03 2014-04-28 Univ Miami Immunotherapy based on allogeneic cancer cells.
WO2009117116A2 (en) 2008-03-20 2009-09-24 University Of Miami Heat shock protein gp96 vaccination and methods of using same
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
JP2012506898A (en) * 2008-10-31 2012-03-22 ノバルティス アーゲー Combination of phosphatidylinositol-3-kinase (PI3K) inhibitor and mTOR inhibitor
EP2370076B1 (en) * 2008-11-28 2017-01-04 Novartis AG Pharmaceutical combination comprising a Hsp 90 inhibitor and a mTOR inhibitor
CN102405057B (en) 2009-03-23 2016-05-25 那尼尔科斯治疗公司 By immunostimulating Hiv Tat derivative polypeptides treatment cancer
WO2011041391A1 (en) 2009-09-29 2011-04-07 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
US11963716B2 (en) 2010-07-19 2024-04-23 Emblation Limited Apparatus and method for the treatment of dermatological diseases or conditions
US9662510B2 (en) 2010-07-19 2017-05-30 Emblation Limited Apparatus and method for the treatment of dermatological diseases or conditions
CN103501807A (en) * 2011-02-23 2014-01-08 迈阿密大学 Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv
US9028884B2 (en) 2013-08-13 2015-05-12 Preventamedics LLC Medical delivery devices and methods for applying a barrier composition to a targeted skin surface
RU2695653C2 (en) 2013-10-04 2019-07-25 Пин Фарма, Инк. Immunostimulating polypeptide derivatives of tat hiv for use in treating cancer
GB2541749B (en) 2015-08-31 2020-12-09 Emblation Ltd An interference suppression apparatus and method
US11497926B2 (en) 2016-08-08 2022-11-15 Emblation Limited Method and apparatus for the treatment, management and/or control of pain
KR20200002862A (en) 2017-03-28 2020-01-08 엠블래이션 리미티드 Stenosis Treatment
US20230241207A1 (en) * 2017-04-03 2023-08-03 Neon Therapeutics, Inc. Protein antigens and uses thereof
CN108409866A (en) * 2018-01-23 2018-08-17 合肥瑞城生生物科技有限公司 A kind of multi-epitope combined peptide for treating and preventing human papilloma virus infection and relevant disease
KR20210044805A (en) 2018-08-06 2021-04-23 닐슨 바이오사이언스, 아이엔씨. Wart treatment
CN114478712B (en) * 2022-03-29 2022-09-23 深圳吉诺因生物科技有限公司 HPV epitope and identification method and application thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666847A (en) 1981-01-16 1987-05-19 Collaborative Research, Inc. Recombinant DNA means and method
DK172882B1 (en) 1983-02-07 1999-09-06 Rothwell Property Ltd DNA containing expression control region from a eukaryotic heat shock gene, vector and eukaryotic cell containing DNAs
US4797359A (en) 1983-05-10 1989-01-10 Board Of Regents, The University Of Texas System Heat shock regulated production of selected and fused proteins in yeast
GB8404280D0 (en) 1984-02-17 1984-03-21 Stanford J L Biological preparations
IL71683A0 (en) 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4784941A (en) 1985-04-08 1988-11-15 Genetic Systems Corporation Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with antibodies to LAV
JPS62164696A (en) 1986-01-06 1987-07-21 エフ．ホフマン　―　ラ　ロシュ　アーゲー Development of htlv-iiigag gene
US4734362A (en) 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4906742A (en) 1986-07-31 1990-03-06 Whitehead Institute For Biomedical Research Encoding antigens of M. Leprae
US6007806A (en) 1986-08-13 1999-12-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
NL8701163A (en) 1986-09-09 1988-04-05 Nederlanden Staat USE OF A PEPTIDE FOR THE PREPARATION OF PREPARATIONS FOR LIGHTING, TREATMENT AND DIAGNOSIS OF AUTOIMMUNE DISEASES, IN PARTICULAR ARTHRITIC CONDITIONS, COMPOUNDS RELATED TO THIS PEPTIDE, AND PHARMACEUTICAL AND DIAGNOSTIC PREPARATORY.
AU1548388A (en) 1987-02-02 1988-08-24 Whitehead Institute For Biomedical Research Mycobacterium tuberculosis genes and encoding protein antigens
US4952395A (en) 1987-02-26 1990-08-28 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US4918166A (en) 1987-04-10 1990-04-17 Oxford Gene Systems Limited Particulate hybrid HIV antigens
US5256767A (en) 1987-06-10 1993-10-26 The Immune Response Corporation Retroviral antigens
NL8703107A (en) 1987-12-22 1989-07-17 Nederlanden Staat POLYPEPTIDES AND DERIVATIVES THEREOF, AND THEIR USE THEREOF IN PHARMACEUTICAL AND DIAGNOSTIC PREPARATIONS.
US5204259A (en) 1988-05-06 1993-04-20 Pharmacia Genetic Engineering, Inc. Methods and systems for producing HIV antigens
DE68924162T2 (en) 1988-06-15 1996-04-25 Medical Res Council STRESS PROTEINS AND USES THEREFOR.
AU5184190A (en) 1989-02-23 1990-09-26 University Of Ottawa Polypeptide having immunological activity for use as diagnostic reagent and/or vaccine
US5114844A (en) 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
CA2063414A1 (en) 1989-06-19 1990-12-20 Richard A. Young Vector-mediated genomic insertion and expression of dna in bcg
GB8919321D0 (en) 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
US5348945A (en) 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
GB9024320D0 (en) 1990-11-08 1990-12-19 Univ London Treatment of uveitis
AU660430B2 (en) 1990-11-08 1995-06-29 Stanford Rook Limited Mycobacterium as adjuvant for antigens
GB2251186A (en) 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
EP0521220A1 (en) 1991-06-14 1993-01-07 Institut Pasteur Recombinant immunogenic actinomycetale
GB9113809D0 (en) 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
IT1262896B (en) 1992-03-06 1996-07-22 CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
WO1993022343A1 (en) 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
GB9211736D0 (en) 1992-06-03 1992-07-15 Univ Cardiff Allergic treatment
US5736146A (en) 1992-07-30 1998-04-07 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
PT700445E (en) 1993-06-04 2002-07-31 Whitehead Biomedical Inst STRESS PROTEINS AND THEIR USES
US5404142A (en) 1993-08-05 1995-04-04 Analog Devices, Incorporated Data-directed scrambler for multi-bit noise shaping D/A converters
ATE303160T1 (en) 1993-08-11 2005-09-15 Jenner Technologies VACCINE AGAINST PROSTATE CANCER
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
IL109790A0 (en) 1994-05-25 1994-08-26 Yeda Res & Dev Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
GB9419979D0 (en) 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
AU4727296A (en) 1995-02-24 1996-09-11 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
CA2229543A1 (en) 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
WO1997026910A2 (en) 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumour vaccine for immunotherapy of malignant tumours
HUP9904137A3 (en) * 1996-07-29 2001-06-28 Cantab Pharmaceuticals Res Ltd Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US6130087A (en) 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
CA2272536A1 (en) 1996-11-26 1998-06-04 Stressgen Biotechnologies Corp. Immune responses using compositions containing stress proteins
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
CA2282426A1 (en) 1997-02-18 1998-08-20 The Whitehead Institute For Biomedical Research Use of heat shock proteins to deliver moieties into cells
KR20060111731A (en) * 1997-08-05 2006-10-27 스트레스젠 바이오테크놀러지스 코포레이션 Immune responses against hpv(human papillomavirus) antigens elicited by compositions comprising a fusion protein comprising an hpv antigen and a stress protein
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
CN1248631A (en) * 1998-09-24 2000-03-29 周国庆 Fusion protein for immunoprophyaxis and immunotherapy of venereal disease and cancer
US6451316B1 (en) 1998-10-05 2002-09-17 University Of Conneticut Health Center Methods for generating antigen-reactive T cells in vitro
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
US6497880B1 (en) 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
EP1196772A2 (en) 1999-07-08 2002-04-17 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
EP1218030A4 (en) 1999-09-10 2004-09-15 Univ Fordham Methods and compositions for the treatment and prevention of graft rejection using heat shock proteins
US20010034042A1 (en) 2000-01-20 2001-10-25 Srivastava Pramod K. Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
WO2001053457A2 (en) 2000-01-21 2001-07-26 University Of Connecticut Health Center Vaccines against neurodegenerative disorders
AU2001227960A1 (en) 2000-01-21 2001-07-31 University Of Connecticut Health Center Heat shock/stress protein complexes as vaccines against neurodegenerative disorders
AU2001229597A1 (en) 2000-01-21 2001-07-31 University Of Connecticut Health Center Compositions and methods to treat neurodegenerative disorders
DK1296711T3 (en) * 2000-06-26 2006-08-28 Stressgen Biotechnologies Corp HPV-E7 for the treatment of human papillomavirus

Similar Documents

Publication Publication Date Title
RU2003101965A (en) TREATMENT OF INFECTION CAUSED BY HUMAN PAPILLOMA VIRUS
JP2004512264A5 (en)
Jagu et al. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines
Kenter et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity
Ohlschlager et al. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice
Yuan et al. Immunization with a pentameric L1 fusion protein protects against papillomavirus infection
Jansen et al. Human papillomavirus vaccines and prevention of cervical cancer
Campo et al. Papillomavirus prophylactic vaccines: established successes, new approaches
HUP0301308A2 (en) Human papilloma virus treatment
CO4810234A1 (en) VACCINES FOR THE TREATMENT OF HUMAN PAPILOMA VIRUSES
US9562075B2 (en) Intradermal HPV peptide vaccination
Kawana et al. Human papillomavirus vaccines: current issues & future
Ma et al. Current status of HPV vaccines
Turner et al. HPV vaccines: translating immunogenicity into efficacy
ES2876036T3 (en) Composition containing a lactic bacteria, oral pharmaceutical composition for use in the treatment of HPV infections and / or HPV-associated tumors and mucosal immunity inducing agent for use in providing mucosal immunity against HPV infection
Schreckenberger et al. Vaccination strategies for the treatment and prevention of cervical cancer
JP4854742B2 (en) Use of Nocardia rubra cell wall skeleton in the preparation of anti-HPV infection drugs
Deresinski Concurrent Plasmodium vivax malaria and dengue
Meyer et al. Cell‐mediated immune response: a clinical review of the therapeutic potential of human papillomavirus vaccination
Kahn et al. Human papillomavirus vaccines and adolescents
KR950031108A (en) Unclassified Haemophilus Influenza P5 Protein Purified as a Vaccine, and Methods for Purification thereof
RU2002111554A (en) VACCINE
Astbury et al. Human papillomavirus vaccination in the prevention of cervical neoplasia
Sin Human papillomavirus vaccines for the treatment of cervical cancer
KR20130142104A (en) Human papillomavirus e7 antigen compositions and uses thereof